NASDAQ: DBVT

DBV Technologies S.A.

Healthcare | Biotechnology

No licensed closing price on file for DBVT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

DBV Technologies S.A. (NASDAQ: DBVT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 10:12 UTC.

What DBV Technologies S.A. does

DBV Technologies is a biopharmaceutical company developing Viaskin, a skin patch technology for treating food allergies and other immune conditions through epicutaneous immunotherapy. The patch delivers allergens to immune cells in the skin without entering the bloodstream, designed to be safer than existing treatments. The company's most advanced product, Viaskin Peanut Patch, has completed multiple clinical trials and is planned for regulatory submission to treat children with peanut allergy.

Summarized from DBV Technologies S.A.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation	8-K 2026-09-30
Return on equity	-87.07%

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-07-31

2026-07-31Chief Medical OfficerSale-464$1.3K
2026-02-02Chief Medical OfficerSale-534$2.6K
2026-01-14DirectorSecond Pre-Funded WarrantOption exercise2,299,656—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

MPM BIOIMPACT LLC3,666,284$60.13M-29.7%
Siren, L.L.C.1,857,362$30.46M0.0%
Vivo Capital, LLC1,844,758$30.25M-30.8%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-06-05Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2026-05-05Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-06-11Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
Seeking Alpha Feed2026-07-16
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
seekingalpha.com2026-06-30
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
Seeking Alpha Feed2026-06-30

Questions this page answers

What does DBV Technologies S.A. do?

DBV Technologies is a biopharmaceutical company developing Viaskin, a skin patch technology for treating food allergies and other immune conditions through epicutaneous immunotherapy.

When did DBVT last file with the SEC?

DBV Technologies S.A.'s most recent SEC filing on record is a 8-K filed 2026-09-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 10:12 UTC. This page is also available as JSON at /api/data?ticker=DBVT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for DBVT and 5,000+ tickers.

Create a free account — keep DBVT

For your agent

GET /api/data?ticker=DBVT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt